Summary
Moberg Pharma AB (publ) (MOBs) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Moberg Pharma AB (publ) ever had a stock split?
Moberg Pharma AB (publ) Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dr. Jonas Ekblom Ph.D. CEO | CBOE Exchange | SE0003613090 ISIN |
| DE Country | 5 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Moberg Pharma AB (publ) operates as a pharmaceutical company with a global reach, focusing on the development and commercialization of medical products. Originally known as Moberg Derma AB (publ), the company underwent a name change in May 2013, signaling a broader focus within the pharmaceutical industry. Since its foundation in 2006, Moberg Pharma has been dedicated to addressing complex medical conditions, with its headquarters located in Bromma, Sweden. The company has successfully positioned itself in both European and international markets, including the United States, by emphasizing research, development, and commercialization of novel treatments.
Products and Services
- MOB-015
A leading product in Moberg Pharma’s portfolio, MOB-015, has reached a pivotal stage in its development. This innovative treatment for nail fungus has successfully completed Phase III clinical trials, marking a significant milestone towards offering patients a new, effective solution for this common but challenging condition. MOB-015’s progress underlines Moberg Pharma AB's commitment to advancing dermatological care through rigorous research and development.
